Samineni, Divya |  Gibiansky, Leonid... -  《Advances in therapy.》 - 2022,39(8) - 3635～3653 - 共19页 - 被引量：3

摘要：Introduction This study aims to investigate |  pharmacokinetics (PK) and exposure-response parameters of the 400 |  mg once-daily venetoclax dose regimen in |  combination with obinutuzumab, which was approved for the |  first-line (1L) treatment of chronic lymphocytic

关键词： Drug safety |  Effectiveness |  Cancer |  Pharmacokinetics |  BCL-2 INHIBITOR |  17P DELETION |  OPEN-LABEL |  CHLORAMBUCIL |  MULTICENTER |  RITUXIMAB...